|
GENOUS™
Our Technology
The world’s first proven AI-powered clinical decision support system for precision oncology
The core value of GenousTM is Digital Drug Assignment (DDA) system, powerful computational tool aiming to optimize treatment decision-making in precision oncology by automated data compilation, evaluation, and synthesis in a knowledge model allowing standardized, personalized treatment decisions based on the totality of available molecular information for any individual patient.
Scientific data
Research, trials, published data, pharma information
Patient Input
Molecular profile Igenetic & protein), Tumor type, Patient history
Genomate it!
34.000 algorithms that perform of calulations
Therapy
General operating principle of Genomate (DDA)
It starts with data
DDA helps oncologists determine the optimal targeted therapy for every cancer patient based on the individual molecular profile of their tumor. Unlike currently available solutions, DDA can combine what we know about the unique combination of genetic alterations found in every patient to make an automated inference about the right personalized therapy.
Patient data
Knowledge base
2.100
compounds
5.508
genes
69.797
mutations
34.437
relations
24.771
evidence
AI algorithms calculate all possibilities
The current system deploys 34,000+ algorithms to match the right targeted therapy to the patient's molecular diagnostic test results out of available treatment options. While recommending therapies, the algorithm considers all functional evidence, all genes and mutations detected - considering each tumor type. The algorithms behind DDA are transparent, unbiased, and based on sound scientific principles. They are the work of more than three decades of scientific research and are backed by clinical trial data.
Driver 1
Driver 2
Driver 3
Target 1
Target 2
Target 3
MTA1
MTA2
MTA3
The most relevant drugs are identified
Instead of reporting cancer gene–treatment associations and related pieces of evidence individually, the system automatically combines all information from thousands of pieces of evidence associated with the totality of genetic alterations in an individual tumor to create a simple score in 20 milliseconds.
Target 1
Target 2
Target 3
Evidence related to
target 1
Evidence related to
target 2
Evidence related to
target 3
DIGITAL DRUG ASSIGNMENT
AI-based computational method for weighing evidence and assigning a mathematical score to each piece of evidence
DDA generates an intuitive report
The output is a personalized report, which provides oncologists with a list of recommended drugs and treatment options tailored to the individual patient's molecular profile. This way, oncologists can enhance their decision-making process and deliver more effective targeted therapies to their patients.
Evidence - based target and hence targeted therapy prioritization (GDS = Genomate Drug Score: Calculated using proprietary, patented algorithm)
Drug negatively associated (contraindication).
This may be the aggregated result of low positive association (e.g. GDS 150) and a strong negative association (e.g. GDS - 1.560)